CD274 and neoplasm: In the Trp53−/− Brca1−/− model, the anti-PD-L1 monotherapy nearly doubled the median survival of tumour-bearing mice (74 days) compared to the isotype control (38 days), making it the most beneficial overall treatment in terms of survival (Fig. 2D).